Table 4.
Treatment efficacy in acquired angioedema C1-inhibitor patients with anti-C1-INH autoantibodies (N = 8)
| Patient | Gender (M/F) |
Type of anti-C1-INH autoantibodies | Untreated attacks (n) |
Mean duration of untreated attacks (h) |
Treated attacks (n) |
Mean duration of treated attacks a (h) |
Mean shortening of attacks with treatment (h, (%)) | Effectively treated attacks b (n (%)) |
|---|---|---|---|---|---|---|---|---|
| 1 | F | IgG | 124 | 72 | 820 | 9.5 | 62.5 (86.8) | 820 (100) |
| 2 | M | IgG, IgM | 208 | 60 | 13 | 79 | −19 (−31.7) | 1 (8.3) |
| 3 | M | IgG | 648 | 84 | 12 | 41.5 | 42.5 (50.6) | 12 (100) |
| 4 | M | IgG, IgM | 79 | 96 | 16 | 26 | 70 (72.9) | 16 (100) |
| 5 | F | IgA | 89 | 84 | 24 | 38 | 46 (54.8) | 22 (91.7) |
| 6 | M | IgG | 59 | 96 | 303 | 24.25 | 71.75 (74.7) | 303 (100) |
| 7 | M | IgG, IgM | 144 | 120 | 71 | 11 | 109 (90.8) | 70 (98.6) |
| 8 | F | IgG, IgM | 283 | 72 | 70 | 51.5 | 20.5 (28.5) | 68 (97.1) |
| Total | – | – | 1634 | – | 1329 | – | – | 1246 (93.8) |
atime between onset of attack and injection + time between injection and resolution of symptoms
bas assessed by the patient
C1-INH = C1-inhibitor; F = Female; Ig = Immunoglobulin; M = Male